# EDGAR Filing Document

**Accession Number:** 0001030617
**File Stem:** 0001104659-25-074695
**Filing Date:** 2025-8
**Character Count:** 12413
**Document Hash:** 612681f8eea9387f8603bdd3edd8ae28
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-074695.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001104659-25-074695

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PRECISION BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0001357874
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90975
- **FILM NUMBER:** 251189352

**BUSINESS ADDRESS:**
- **STREET 1:** 302 EAST PETTIGREW STREET
- **STREET 2:** SUITE A-100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27701
- **BUSINESS PHONE:** 919-314-5512

**MAIL ADDRESS:**
- **STREET 1:** 302 EAST PETTIGREW STREET
- **STREET 2:** SUITE A-100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27701
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVARTIS PHARMA AG
- **CENTRAL INDEX KEY:** 0001030617

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **STREET 2:** CH-4002
- **CITY:** BASEL
- **STATE:** V8
- **BUSINESS PHONE:** 212-830-2474

**MAIL ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **STREET 2:** CH-4002
- **CITY:** BASEL
- **STATE:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVARTIS INC
- **DATE OF NAME CHANGE:** 19970114

## Exhibit 99.1

**EXHIBIT 1**

**EVIDENCE OF SIGNATORY AUTHORITY**

<u>Excerpt from Commercial Register of Novartis Pharma AG</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Identification number | Legal status | Entry | Cancelled | Carried CH-270.3.004.604-7 |  |
|  |  |  |  | from: CH-270.3.004.604-7/b | **1** |
| **CHE-106.052.527** | **Limited or Corporation** | 25.10.1989 | | on: | |

---

All data

---

| | | | | |
|:---|:---|:---|:---|:---|
| In | Ca | Business name | Ref | Legal seat |
| 1 |  | **Novartis Pharma AG** | 1 | Basel |
| 1 | | (Novartis Pharma SA) (Novartis Pharma Inc.) | | |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHE-106.052.527** |  | **Novartis Pharma AG** |  | **Basel** | **3** |
| All data |  |  |  |  |  |
| In | Mo Ca | Personal Data | Function | Signature | Signature |
|  | 58 | Rehm, Christian Jakob, von Illanz/Glion, in Cham | secretary (out of the board) | joint signature at two | joint signature at two |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHE-106.052.527** |  | **Novartis Pharma AG** |  | **Basel** | **3** |
| All data |  |  |  |  |  |
| In | Mo Ca | Personal Data | Function | Signature | Signature |
| 55 |  | Foertsch, Lukas, von Zürich, in Sissach |  | joint signature at two | joint signature at two |

---

<u>Excerpt from Commercial Register of Novartis AG</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Identification number | Legal status | Entry | Cancelled | Carried CH-270.3.002.061-2 |  |
|  |  |  |  | from: CH-270.3.002.061-2/a | **1** |
| **CHE-103.867.266** | **Limited or Corporation** | 01.03.1996 | | on: | |

---

All data

---

| | | | | |
|:---|:---|:---|:---|:---|
| In | Ca | Business name | Ref | Legal seat |
| 1 |  | **Novartis AG** | 1 | Basel |
| 1 | | (Novartis SA) (Novartis Inc.) | | |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHE-103.867.266** |  | **Novartis AG** |  | **Basel** | **3** |
| All data |  |  |  |  |  |
| In | Mo Ca | Personal Data | Function | Signature | Signature |
| 1 |  | Rehm, Christian Jakob, von Illanz/Glion, in Cham |  | joint signature at two | joint signature at two |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHE-103.867.266** |  | **Novartis AG** |  | **Basel** | **3** |
| All data |  |  |  |  |  |
| In | Mo Ca | Personal Data | Function | Signature | Signature |
| 1 |  | Weiss, Daniel Andreas, von Basel, in Biel-Benken |  | joint signature at two | joint signature at two |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Issuer:** PRECISION BIOSCIENCES INC

**Title of Class of Securities:** Common stock, par value $0.000005 per share

**CUSIP Number:** 74019P207

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Novartis Pharma AG | Names of Reporting Persons<br>Novartis Pharma AG |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>V8 | Citizenship or Place of Organization<br>V8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>413581.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>413581.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>413581.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>413581.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.7% | Percent of Class Represented by Amount in Row (9)<br>3.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

---

| 1. | Names of Reporting Persons<br>Novartis AG | Names of Reporting Persons<br>Novartis AG |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>V8 | Citizenship or Place of Organization<br>V8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>413581.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>413581.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>413581.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>413581.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.7% | Percent of Class Represented by Amount in Row (9)<br>3.7% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, CO | Type of Reporting Person (See Instructions)<br>HC, CO |

---

**Item 1(a). Name of Issuer:**
PRECISION BIOSCIENCES INC

**Item 1(b). Address of Issuer's Principal Executive Offices:**
302 EAST PETTIGREW STREET SUITE A-100, DURHAM, NC, 27701

**Item 2(a). Name of Person Filing:**
This statement is filed on behalf of the following persons with respect to the shares of Common Stock of the Issuer:

(i)  Novartis Pharma AG, a Swiss corporation ("Novartis Pharma"), with respect to shares held by it; and

(ii)  Novartis AG, a Swiss corporation ("Novartis"), as the publicly-owned parent of Novartis Pharma, with respect to the shares held by Novartis Pharma.

The foregoing persons are hereinafter referred to collectively as the "Reporting Persons."

**Item 2(b). Address of Principal Business Office:**
The address of the principal business offices of the Reporting Persons is Lichtstrasse 35, CH-4056 Basel, Switzerland.

**Item 2(c). Citizenship:**
Novartis Pharma is a corporation organized under the laws of Switzerland and is a direct wholly-owned subsidiary of Novartis.

Novartis is a corporation organized under the laws of Switzerland and is the publicly-owned parent of Novartis Pharma.

**Item 2(d). Title of Class of Securities:**
Common stock, par value $0.000005 per share

**Item 2(e). CUSIP Number:**
74019P207

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

The information required by Items 4(a)-(c) with respect to each Reporting Person is set forth in Rows 5through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported arebased on 11,088,234 outstanding shares of Common Stock, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025.

**(b) Percent of class:**

—

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Novartis Pharma AG**

**Date:** 08/05/2025

**By:** /s/ Christian Rehm

**Name & Title:** Christian Rehm / Authorised Signatory

**Novartis AG**

**Date:** 08/05/2025

**By:** /s/ Christian Rehm

**Name & Title:** Christian Rehm / Authorised Signatory